Postnatal ductal closure is stimulated by rising oxygen tension and withdrawal of
vasodilatory mediators (prostaglandins, nitric oxide, adenosine) and by vasoconstrictors …

Preterm infants are at increased risk for patent ductus arteriosus (PDA). Prolonged exposure
to PDA may be deleterious and has been associated with neonatal morbidity and mortality …

Background Much controversy exists about the optimal management of a patent ductus
arteriosus (PDA) in preterm infants, especially in those born at a gestational age (GA) less …

METHODS: Thrombocytopenic (< 100 000 per µL) preterm neonates with hs-PDA were
enrolled and randomly allocated to the liberal and standard transfusion groups: 22 in each …

To evaluate national epidemiologic data on infants treated for patent ductus arteriosus
(PDA) in Korea and analyze outcomes associated with different PDA treatments. We …

Background The optimal treatment strategy for patent ductus arteriosus (PDA) in extremely
preterm infants is currently highly controversial. This study aimed to evaluate the association …

Objective: This study aims to evaluate outcome after conservative management (no
pharmacological/surgical intervention other than fluid restriction, diuretics, or ventilator …

BACKGROUND Patent ductus arteriosus (PDA) treatment is common among very low birth
weight (VLBW) infants. Given limitations in evidence, controversy exists regarding treatment …

Context: There is an ongoing debate on the optimal management of patent ductus arteriosus
(PDA) in preterm infants. Identifying subgroup of infants who would benefit from …

Background Continuous positive airway pressure (CPAP) is associated with marginal
decrease in chronic lung disease (CLD). This study aims to report outcomes, with focus on …